Biovica International

Biovica International is a Swedish life science company focused on blood-based biomarker assays for monitoring cancer treatment response. Its core product, DiviTum TKa, is used in clinical settings and in pharmaceutical development programs, with operations centered in Sweden and the United States.

— Biovica International
%
Clinical diagnostics70% DiviTum TKa testing used by clinicians to monitor cancer treatment response.
Pharma Services30% Biomarker testing, study support, and consulting for pharma and biotech trials.

Biovica sells primarily to healthcare providers and clinical users in the U.S. who use DiviTum TKa to monitor breast...

  • U.S. clinical usersprimary

    Clinicians and laboratories buying DiviTum TKa to monitor cancer treatment response in practice.

  • Pharmaceutical companiesprimary

    Drug developers using TKa testing, study support, and biomarker services in clinical programs.

  • Biotechnology companiessecondary

    Smaller oncology developers using the platform for exploratory and validation studies.

  • Academic and research institutionssecondary

    Researchers buying assays or services for clinical studies and biomarker research.

  • CROssecondary

    Contract research organizations sourcing assay kits or centralized testing for sponsors.

Biovica is headquartered in Uppsala, Sweden, with R&D and production based there and an office and laboratory in San...

  • •Headquartered in Uppsala, Sweden, with R&D and production there
  • •San Diego, California hosts the U.S. office and laboratory
  • •The United States is the main commercial market for DiviTum TKa
  • •Europe is served through distributor and laboratory partnerships
  • •Future expansion includes Japan and other international markets

Biovica’s strategy is to expand adoption of DiviTum TKa in breast cancer, especially in the U.S...

01
U.S. commercializationshort-term

The U.S. is the main market and the CLIA lab model supports direct commercialization.

02
Pharma Services expansionmedium-term

Pharma collaborations diversify revenue and can create future CDx opportunities.

03
Clinical evidence generationmedium-term

Published and real-world evidence supports physician adoption and payer acceptance.

04
Geographic and indication expansionlong-term

Broader market access can increase the addressable market beyond the U.S. breast cancer base.

Biovica depends on adoption of a specialized biomarker test, so commercial execution, reimbursement, and clinical...

high

Commercial adoption risk

Revenue depends on clinicians and labs adopting a biomarker test in routine care.

Scope
U.S. clinical market
Materiality
high
high

Reimbursement and payer risk

The U.S. model relies on reimbursement levels that support clinical use and scaling.

Scope
U.S. market access
Materiality
high
high

Regulatory and compliance risk

The business operates under CLIA/LDT frameworks and may face changing diagnostics rules.

Scope
United States and future international markets
Materiality
high
medium

Pharma partnership concentration

A meaningful part of growth depends on onboarding and retaining large pharma customers.

Scope
Pharma Services
Materiality
medium
medium

Currency risk

Operations and sales span Sweden, the U.S., and Europe, creating USD/EUR exposure.

Scope
SEK, USD, EUR
Materiality
medium
Revenue recognition
Affects quarterly revenue timing and comparability
Capitalized development expenditure
Affects intangible assets, amortization, and operating expense
Intangible asset impairment
Could create non-cash write-downs if assumptions weaken
Inventory valuation
Can affect gross margin and write-downs
Share-based compensation
Affects operating expenses and equity dilution

BIOVIE INC.

BIVI · Pharmaceutical Preparations

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

BioInvent International

BINV.ST · Health Care

IOVANCE BIOTHERAPEUTICS, INC.

IOVA · Biological Products, (No Diagnostic Substances)

CG Oncology, Inc.

CGON · Biological Products, (No Diagnostic Substances)

BioGaia

BIOG-B.ST · Health Care

: 11/08/2026